{"abstract": "A reverse merger in biotechnology is meant to help a private company go public when the investment climate is poor for an initial public offering.", "web_url": "https://www.nytimes.com/2009/03/10/business/10biocashside.html", "snippet": "A reverse merger in biotechnology is meant to help a private company go public when the investment climate is poor for an initial public offering.", "lead_paragraph": "It is called a reverse merger. And for a failing public biotechnology company, it can represent one last roll of the dice. ", "print_section": "B", "print_page": "4", "source": "The New York Times", "multimedia": [], "headline": {"main": "Taking a Chance on a Reverse Merger", "kicker": null, "content_kicker": null, "print_headline": "Taking a Chance on a Reverse Merger", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 1, "major": "N"}, {"name": "organizations", "value": "Schering Plough Corp", "rank": 2, "major": "N"}, {"name": "organizations", "value": "Merck & Company Inc", "rank": 3, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 4, "major": "N"}, {"name": "organizations", "value": "NitroMed, Incorporated", "rank": 5, "major": "N"}, {"name": "subject", "value": "Biotechnology", "rank": 6, "major": "N"}], "pub_date": "2009-03-09T21:34:39+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Andrew Pollack", "person": [{"firstname": "Andrew", "middlename": null, "lastname": "Pollack", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/9a62ba71-ed36-5ec3-8a6a-d9ac8a6f2d76", "word_count": 485, "uri": "nyt://article/9a62ba71-ed36-5ec3-8a6a-d9ac8a6f2d76"}